A cDNA clone encoding a glycine transporter has been isolated from rat brain by a combined PCR and plaque-hybridization strategy. mRNA synthesized from this clone (designated GLYT1) directs the expression of sodiumand chloride-dependent, high-affinity uptake of [3H]glycine by Xenopus oocytes.
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Glycine transport mediated by clone GLYT1 is blocked by sarcosine but is not blocked by methylaminoisobutyric acid or L-alanine, a substrate specificity similar to that described for a previously identified glycine-uptake system called system Gly. In situ hybridization reveals that GLYT1 is prominently expressed in the cervical spinal cord and brainstem, two regions of the central nervous system where glycine is a putative neurotransmitter. GLYT1 is also strongly expressed in the cerebellum and olfactory bulb and is expressed at lower levels in other brain regions. The open reading frame of the GLYT1 cDNA predicts a protein containing 633 amino acids with a molecular mass of =70 kDa. The primary structure and hydropathicity profile of GLYT1 protein reveal that this protein is a member of the sodium-and chloride-dependent superfamily of transporters that utilize neurotransmitters and related substances as substrates.
Termination of synaptic activity is thought to occur through removal of neurotransmitter from the synaptic cleft by ioncoupled, high-affinity neurotransmitter transport proteins (neurotransmitter transporters) located in neuronal and glial plasma membranes. Drugs that block the action of these transporters can modulate neural function, probably by increasing the duration of neurotransmitter action. Some neurotransmitter transporters, such as those for the monoamines, are the sites of action for clinically important drugs (for example, antidepressants) (1), as well as drugs of abuse (for example, cocaine) (2) . Other neurotransmitter transporters, such as those for the inhibitory amino acid y-aminobutyric acid (GABA), are potential targets for drugs with anticonvulsant properties (3) . Therefore, an understanding of the structure and function of neitrotransmitter transporters may lead to a better understanding of synaptic regulation and could also provide a rational basis for the development of additional, more-specific anti-transporter drugs.
The recent isolation of cDNA clones encoding transporters for GABA (4), the monoamines norepinephrine, dopamine, and serotonin (5-10), and a nonneurotransmitter, betaine (11) , has revealed that these carriers comprise a superfamily of homologous proteins. Predictions of membrane topology suggest that these transporters all contain =12 membranespanning domains, a structural motif shared by a number of carriers that, however, share little mutual sequence homology. The amino acid-sequence identity between the known members of the neurotransmitter transporter superfamily ranges from "-44% for the GABA transporter (GAT1) versus the norepinephrine transporter (NET1) to =64% for NET1 versus the dopamine transporter (DAT1), indicating that subfamilies exist within the superfamily. In addition to an overall homology, members of this superfamily contain several regions of sequence identity distributed throughout the length of the protein. These regions can be used to design PCR primers which can be employed to clone additional members of the superfamily from brain and other tissues. In this paper we report the results of such a cloning approach, which has yielded a rat brain cDNAt encoding a sodium-and chloride-dependent high-affinity glycine transporter.
MATERIALS AND METHODS
RNA Isolation and PCR. Total RNA was prepared from C6 glioma cells and rat tissues by the acid guanidinium/phenol method (12) . cDNA was synthesized directly from 5 Mg of total RNA or mRNA and amplified by the PCR and standard protocols. The primers chosen for amplification consisted of a 128-fold degenerate sense primer corresponding to bases 375-394 of GAT1 with the sequence (5'--3') GAG CTC GTC GAC AAG AAC GG(TCAG) GG(TCAG) GG(TCAG) GC(TC) TT and a 48-fold degenerate antisense primer corresponding to bases 1108-1030 ofGAT1 with the sequence (5' -* 3') GGG CCC TCT AGA AA (GA)AT CTG (GA)GT (GAT)GC (GA)GC (AG)TC. The size range was screened with the same random primerlabeled PCR product used to probe the RNA blot and under the same hybridization conditions. Six positive clones were identified. The phagemids were rescued from each clone and used for further analysis. Dideoxynucleotide DNA sequencing was done by a combination of nested deletions and primer walks.
Xenopus Oocyte Expression and Transport Assays. Xenopus oocytes were defolliculated and maintained in ND96 medium/5% horse serum (14) . mRNA was synthesized from 5 ug of plasmid template and gel-purified on a Sephadex G-50 spin column. Ten nanograms of mRNA was microinjected into each oocyte, and the samples were allowed to translate for 4-7 days. Controls consisted of oocytes injected with 50 nl of water.
[3H]Glycine and drugs were added to a total volume of 50 pl, and uptake assays were done as described (5) . Each data point represents the mean of three to five oocytes.
In Situ Hybridization. Rat brain and cervical spinal cord were fixed with 4% paraformaldehyde and processed as described (15 (19) , glutamate (19) , and glycine (20, 21) . We, therefore, chose these cells as a potential source of additional members of the neurotransmittertransporter superfamily. When RNA from C6 cells is amplified by the PCR with the degenerate primers described in Materials and Methods, a major product of -700 bp is seen (Fig. 1A) . The nucleotide sequence of this PCR product encodes a peptide with significant homology to both GAT1 and NET1 proteins (data not shown). RNA blot analysis with the PCR product as a probe reveals a single transcript of -3.3 kilobases (kb) in C6 cell mRNA and in rat forebrain and cerebellum mRNA (Fig. 1B) . There is a barely detectable signal in rat liver mRNA and no detectable signal in kidney mRNA. This result indicated that the gene corresponding to this PCR product is expressed in brain but is not expressed (or is expressed at low levels) in nonneural tissue. Therefore, a size-selected AZAP rat brain cDNA library was screened with the C6 cell PCR product, and six positive clones were 
from these clones indicated that five of the six clones were clearly related to each other and to the original PCR product, whereas the sixth represented an unrelated clone. One of these five clones (clone 9-iB) appeared to be full-length at the 5' end of the open reading frame, and this clone was chosen for further analysis and expression.
Functional Expression. Oocytes injected with 9-lB mRNA were tested for their ability to take up radiolabeled neurotransmitters or related compounds. Fig. 2A tkM [3H] glycine. This result indicated that clone 9-lB encodes a glycine transporter, and it was designated GLYT1.
Uptake by oocytes injected with GLYT1 mRNA depends on both extracellular sodium and extracellular chloride, indicating that the transporter encoded by this clone mediates ion-coupled active transport of [3H]glycine (Fig. 2B) . Interestingly, the moderate level of [3H]glycine uptake by control oocytes is also sodium-and chloride-dependent, indicating that Xenopus oocytes possess an endogenous transport system for glycine. This fact is not surprising because uptake systems for metabolically important amino acids are found in both neural and nonneural tissues (22) . Oocytes injected with GLYT1 mRNA take up [3H]glycine by a high-affinity mechanism ( Fig. 3 A and B) . Kinetic analysis revealed a Km of 33 ± 8 uM (mean ± SEM, n = 3), which is similar to the Km values reported previously for high-affinity glycine uptake in the central nervous system (23) (24) (25) . This Km value is almost 3-fold lower than that reported for [3H]glycine uptake by C6 glioma cells (Km = 95 ,IM) (21) . The Vm,, value for the cloned transporter varied, depending on the batch of oocytes, from 120 to 390 pmol per oocyte per hr (mean = 246 ± 78). The oocyte glycine transporter also appears to be a high-affinity transporter with a Km of =20 ,uM and a Vma. of =20 pmol per oocyte per hr (data not shown).
At least three uptake systems able to transport glycine, termed system Gly, system ASC, and system A, have been demonstrated in a variety of tissues and cell types by using amino acids and amino acid analogs as substrates and competitive inhibitors (26) . Therefore, the substrate specificity of GLYT1 was examined by using several of the subtypespecific compounds ( (21) . However, the substrate specificity of GLYT1 differs from that described in earlier work on the rat spinal cord (23), where sarcosine was reported to have no significant inhibitory effect at concentrations as high as 1 mM. Thus, GLYT1 may represent one of several glycine-transporter subtypes expressed in brain.
The oocyte endogenous glycine transporter shows an inhibition profile different from GLYT1. The former is inhibited almost 90%o by L-alanine (Fig. 2C) , L-serine, and L-Cysteine (data not shown). This transporter is not blocked by methylaminoisobutyric acid and is only partially inhibited by sarcosine (Fig. 2C) (Fig. 4) . The protein contains four putative N-glycosylation sites located in a region, which, for GATi, is proposed to form a large extracellular loop (4) . There are five putative protein kinase C phosphorylation sites. A Kyte-Doolittle analysis of GLYT1 yielded a hydrophobicity profile almost identical to that seen for GATi (4) and other members of this transporter superfamily, suggesting that the membrane topology of GLYT1 is similar to proposed models (4, 5, 8 (including the spinal trigeminal nucleus, Fig. 5A ), the cerebellum (Fig. 5B) , and the olfactory bulb (Fig. SC) . Lighter labeling is present in other medullary, pontine, midbrain, thalamic, and hypothalamic nuclei (data not shown). Labeling above background could not be detected in the cerebral cortex, caudate-putamen and globus pallidus, hippocampal formation, or septal nuclei. Furthermore, there is no specific labeling in white-matter fiber tracts. No specific labeling was observed in control sections incubated with sense RNA probes (Fig. SD) (27) and contain glycine immunoreactivity (28, 29) ; thus, this finding provides further evidence for the possibility of multiple glycine-transporter subtypes. In the olfactory bulb, there is prominent labeling of many cells located in the glomerular layer (Fig. 5C ). Labeled cells also occur in the external plexiform layer, the mitral cell body layer, and the granule cell layer (Fig. 5C ). Although localization of [3H]glycine uptake in the olfactory bulb is equivocal (30), recent immunocytochemical studies suggest that the periglomerular neurons and some cells in the granule cell layer contain glycine (29) . As in the other labeled regions, we cannot rule out the possibility that some glia cells in the olfactory bulb express GLYT1.
Availability of the GLYT1 cDNA should facilitate our understanding of glycinergic metabolism in the central nervous system. In addition, further in situ hybridization studies of GLYT1 expression will undoubtedly aid in identifying putative glycinergic neurons in the spinal cord, the brainstem, and in forebrain structures not conventionally associated with glycinergic neurotransmission.
